XML 76 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Segment information (Tables)
12 Months Ended
Dec. 31, 2024
Segment information  
Schedule of segment financial information

The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):

Year Ended December 31, 

2024

    

2023

Collaboration revenue

$

9,041

$

14,018

Less:

In-process research and development

(152,344)

(80,802)

Direct research and development expenses(1)

Varegacestat

(27,954)

IM-1021

(24,130)

IM-3050

(13,359)

Other

(35,335)

(11,278)

Indirect research and development(2)

(28,764)

(11,811)

General and administrative(3)

(32,955)

(19,657)

Total operating expenses

(314,841)

(123,548)

Loss from operations

(305,800)

(109,530)

Interest income

12,837

2,724

Net loss

$

(292,963)

$

(106,806)